Redeye initiates coverage of Lipum, a Swedish biotech company offering a unique approach to the USD 60 billion-plus inflammatory diseases market. Lipum is establishing a unique platform which will be the key driver for continued development and long-term growth. With lead candidate, SOL-116, now entering the clinic, we argue it has the potential to mark a new era in rheumatoid arthritis (RA). Should it manage to deliver encouraging clinical data, it could catch the eye of large industry players.